NCT Number: NCT00279721
Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
About this study
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence
Exclusion criteria
- medullary or anaplastic thyroid cancer, unresectable
Treatment and study plan
Primary outcomes
-
toxicity according to RTOG criteria
-
locoregional control
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Alberta Health services
Other
Registry information
Official study title
Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Important dates
- Study start
- 2006
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- Jan 20, 2006
- Registry last updated
- Jan 19, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
NCT00467506
Endocrine Gland Neoplasms, Endocrine System Diseases
Caen, France
View Trial DetailsA Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
NCT05241834
Bronchial Neoplasms, Carcinoma, Bronchogenic
Los Angeles, California, United States
View Trial DetailsGenetic Susceptibility to Radiation Induced Thyroid Cancer
NCT04139096
Disease Attributes, Disease Susceptibility
Villejuif, Val de Marne, France
View Trial DetailsThyroidectomy-specific Enhanced Recovery After Surgery (ERAS) Protocol
NCT07575243
Endocrine Gland Neoplasms, Endocrine System Diseases
Asyut, Asyut Governorate, Egypt
View Trial Details